MX2019005269A - Formulaciones estables de dominios variables sencillos de inmunoglobulina y usos de las mismas. - Google Patents

Formulaciones estables de dominios variables sencillos de inmunoglobulina y usos de las mismas.

Info

Publication number
MX2019005269A
MX2019005269A MX2019005269A MX2019005269A MX2019005269A MX 2019005269 A MX2019005269 A MX 2019005269A MX 2019005269 A MX2019005269 A MX 2019005269A MX 2019005269 A MX2019005269 A MX 2019005269A MX 2019005269 A MX2019005269 A MX 2019005269A
Authority
MX
Mexico
Prior art keywords
variable domains
single variable
immunoglobulin single
formulations
stable
Prior art date
Application number
MX2019005269A
Other languages
English (en)
Inventor
Meyvis Yves
De Brabandere Veronique
Ulrichts Hans
Brige Ann
Callewaert Filip
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of MX2019005269A publication Critical patent/MX2019005269A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención se refiere a formulaciones estables de polipéptidos, por ejemplo, dominios variables sencillos de inmunoglobulina, en particular dominios variables sencillos de inmunoglobulina dirigidos contra el Factor de von Willebrand (vWF). La invención proporciona formulaciones las cuales son estables durante el almacenamiento por periodos prolongados de tiempo y sobre un intervalo amplio de temperaturas. Las formulaciones de la invención aseguran una estabilidad alta del polipéptido, permitiendo ciclos de congelación-descongelación múltiples sin deterioro químico o físico, y proporcionan estabilidad con relación a la tensión mecánica, tal como tensión por sacudida, corte o agitación. Son adecuadas para preparaciones de diagnóstico y farmacéuticas y compatibles con diluyentes farmacéuticamente aceptables.
MX2019005269A 2013-05-17 2015-11-13 Formulaciones estables de dominios variables sencillos de inmunoglobulina y usos de las mismas. MX2019005269A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361824523P 2013-05-17 2013-05-17

Publications (1)

Publication Number Publication Date
MX2019005269A true MX2019005269A (es) 2019-09-04

Family

ID=49304267

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015015722A MX364664B (es) 2013-05-17 2014-05-16 Formulaciones estables de dominios variables sencillos de inmunoglobulina y usos de las mismas.
MX2019005269A MX2019005269A (es) 2013-05-17 2015-11-13 Formulaciones estables de dominios variables sencillos de inmunoglobulina y usos de las mismas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015015722A MX364664B (es) 2013-05-17 2014-05-16 Formulaciones estables de dominios variables sencillos de inmunoglobulina y usos de las mismas.

Country Status (25)

Country Link
US (2) US10035862B2 (es)
EP (2) EP3511018B1 (es)
JP (2) JP6433986B2 (es)
KR (1) KR102166399B1 (es)
CN (3) CN110063935B (es)
AU (3) AU2014267222B2 (es)
BR (1) BR112015028411B1 (es)
CA (1) CA2912670A1 (es)
CY (1) CY1122090T1 (es)
DK (1) DK2996720T3 (es)
ES (2) ES2731922T3 (es)
HK (1) HK1218258A1 (es)
HR (1) HRP20190954T1 (es)
HU (1) HUE044392T2 (es)
LT (1) LT2996720T (es)
MX (2) MX364664B (es)
NL (1) NL1040254C2 (es)
PH (1) PH12015502591B1 (es)
PL (2) PL3511018T3 (es)
PT (2) PT2996720T (es)
RS (1) RS58857B1 (es)
RU (1) RU2671977C2 (es)
SI (1) SI2996720T1 (es)
TR (1) TR201908663T4 (es)
WO (1) WO2014184352A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
WO2016097313A1 (en) 2014-12-19 2016-06-23 Ablynx N.V. Cysteine linked nanobody dimers
CN111035754A (zh) * 2016-03-23 2020-04-21 兆科药业（合肥）有限公司 抗血小板溶栓素在制备治疗血栓性血小板减少性紫癜的药物中的应用
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
CN110121340B (zh) * 2016-11-02 2023-03-31 波拉里集团 聚乙二醇化精氨酸脱亚氨酶的调配物
BR112020015991A2 (pt) 2018-02-06 2020-12-15 Ablynx N.V. Métodos de tratamento de episódio inicial de ttp com domínios variáveis únicos de imunoglobulina
AU2019299217A1 (en) 2018-07-03 2021-01-14 Fennec Pharmaceuticals, Inc. Formulations of anhydrous sodium thiosulfate
CA3147678A1 (en) * 2018-09-05 2020-03-12 Solomon OKBAZGHI Formulations of immunoglobulin a
EP3865154A4 (en) * 2018-10-10 2022-11-09 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY FAB FRAGMENT COMPLEX AT LABELED ANTI-HUMAN SITE
CN110564841A (zh) * 2019-09-19 2019-12-13 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 脑缺血相关基因作为缺血性卒中行为学特征分析的生物标记的应用
CN110624105B (zh) * 2019-09-24 2021-06-11 苏州大学 血管性血友病因子的结构敏感多肽抗原的序列
CN113908254A (zh) * 2021-10-19 2022-01-11 山西锦波生物医药股份有限公司 一种干粉吸入剂及其制备方法和用途
CN115850493B (zh) * 2022-11-08 2024-03-12 江苏耀海生物制药有限公司 一种二价纳米抗体Cablivi的分离纯化方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
DE69534318T2 (de) 1994-05-18 2006-04-20 Nektar Therapeutics, San Carlos Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ATE374248T1 (de) 1996-06-27 2007-10-15 Vlaams Interuniv Inst Biotech Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
DE69841562D1 (de) 1997-10-27 2010-04-29 Bac Ip Bv Multivalente antigenbindende proteine
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
EP0967284A1 (en) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
BR9916765A (pt) 1999-01-05 2001-09-25 Unilever Nv Processo para produzir um material imunoadsorvente, uso de uma proteìna que é ligada por meio de uma ligação covalente a um fragmento de anticorpo, material imunadsorvente, uso de um material, e, kit de teste diagnóstico
EP1144616B2 (en) 1999-01-19 2009-01-14 Unilever Plc Method for producing antibody fragments
NZ513356A (en) 1999-02-05 2004-01-30 Univ Leiden Method of modulating metabolite biosynthesis in recombinant cells using an AP2-domain transcription factor that is involved in the response of a plant cell to a jasmonate
US6617122B1 (en) 1999-03-15 2003-09-09 Xenon Genetics, Inc. Process for identifying modulators of ABC1 activity
EP1169453A1 (en) 1999-04-22 2002-01-09 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
AR024576A1 (es) 1999-06-18 2002-10-16 Univ Washington Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une elatp
AU6322900A (en) 1999-08-02 2001-02-19 Keygene N.V. Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
DK1233987T3 (da) 1999-11-29 2009-09-28 Bac Ip B V Immobiliserede enkelt-domæne antigenbindende molekyler
AU1859201A (en) 1999-11-29 2001-06-12 Unilever Plc Immobilisation of proteins
ES2324280T3 (es) 2000-03-14 2009-08-04 Unilever N.V. Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
WO2002048193A2 (en) 2000-12-13 2002-06-20 Unilever N.V. Camelidae antibody arrays
EP2281837B1 (en) 2001-08-10 2016-10-05 Aberdeen University Antigen binding domains from fish
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
US6723359B2 (en) 2001-10-18 2004-04-20 Firmenich Sa Spray-dried compositions and method for their preparation
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
WO2003050531A2 (en) 2001-12-11 2003-06-19 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
CA2471116A1 (en) 2001-12-21 2003-07-03 Serge Muyldermans Method for cloning of variable domain sequences
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
GB0202633D0 (en) * 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
EP1527346B1 (en) 2002-08-07 2011-06-08 Ablynx N.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
JP2006512910A (ja) 2002-10-23 2006-04-20 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ａ３４およびａ３３様３ｄｎａ、タンパク質、それらに対する抗体、ならびに同一物を使用した治療方法
AU2003286004A1 (en) 2002-11-08 2004-06-07 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
MXPA05004955A (es) 2002-11-08 2005-11-17 Ablynx Nv Anticuerpos de region unica dirigidos contra el factor-alfa de necrosis de tumor y usos de estos.
US20060228355A1 (en) 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
US20080107601A1 (en) 2004-10-13 2008-05-08 Ablynx N.V. Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease
WO2006074947A2 (en) 2005-01-14 2006-07-20 Ablynx N.V. METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
EP1844073A1 (en) 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
MX363423B (es) 2005-05-18 2019-03-22 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
CN101213214B (zh) * 2005-05-20 2014-06-25 埃博灵克斯股份有限公司 针对冯威勒布兰特因子的单一结构域vhh抗体
JP5085322B2 (ja) * 2005-06-10 2012-11-28 中外製薬株式会社 ｓｃ（Ｆｖ）２を含有する医薬組成物
JP2009529339A (ja) 2006-03-13 2009-08-20 アブリンクス エン．ヴェー． Ｉｌ−６を標的とするアミノ酸配列およびそれを含みｉｌ−６介在シグナル伝達に関連する疾患および疾病を治療するポリペプチド
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
UA96473C2 (ru) * 2007-03-22 2011-11-10 Имклоун Ллк Жидкая стойкая композиция, которая содержит антитело imc-а12
EP3936116A1 (en) * 2007-12-28 2022-01-12 Takeda Pharmaceutical Company Limited Rrecombinant vwf containing formulations
WO2009115614A2 (en) 2008-03-21 2009-09-24 Ablynx Nv Von willebrand factor specific binders and methods of use therefor
AU2009237662A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
TWI670072B (zh) * 2008-10-21 2019-09-01 美商巴克斯歐塔公司 凍乾的重組ｖｗｆ調配物
BR122018013284B1 (pt) * 2008-10-29 2022-03-03 Ablynx N.V Formulações de moléculas de ligação ao antígeno de domínio único, seu método de formulação e seu uso, kit ou artigo de fabricação, bem como método para preparar uma formulação reconstituída contendo uma molécula de sdab
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US20120321640A1 (en) 2009-12-01 2012-12-20 Ablynx N.V. Von willebrand factor specific binding agents and uses thereof
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
PL3501499T3 (pl) * 2010-02-11 2023-01-09 Ablynx Nv Sposoby i kompozycje do wytwarzania aerozoli
US20120225072A1 (en) * 2011-03-02 2012-09-06 Ablynx N.V. Stable formulations of immunoglobulin single variable domains and uses thereof
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.

Also Published As

Publication number Publication date
JP6433986B2 (ja) 2018-12-05
EP2996720A1 (en) 2016-03-23
CY1122090T1 (el) 2020-11-25
JP6952019B2 (ja) 2021-10-20
SI2996720T1 (sl) 2019-07-31
RU2018137504A3 (es) 2021-12-28
CA2912670A1 (en) 2014-11-20
CN105339003B (zh) 2018-11-20
PL3511018T3 (pl) 2022-01-10
EP3511018A1 (en) 2019-07-17
CN110037983A (zh) 2019-07-23
AU2014267222A1 (en) 2015-11-12
AU2019201307A1 (en) 2019-03-14
PT3511018T (pt) 2021-10-15
DK2996720T3 (da) 2019-06-24
RU2015154214A (ru) 2017-06-22
TR201908663T4 (tr) 2019-07-22
US20160090424A1 (en) 2016-03-31
ES2895150T3 (es) 2022-02-17
RS58857B1 (sr) 2019-07-31
HK1218258A1 (zh) 2017-02-10
BR112015028411A2 (pt) 2017-12-12
US10035862B2 (en) 2018-07-31
MX364664B (es) 2019-05-03
KR102166399B1 (ko) 2020-10-16
AU2014267222B2 (en) 2018-12-13
LT2996720T (lt) 2019-07-10
RU2671977C2 (ru) 2018-11-08
PL2996720T3 (pl) 2019-09-30
AU2019201307B2 (en) 2021-01-28
KR20160007657A (ko) 2016-01-20
MX2015015722A (es) 2016-03-16
PH12015502591A1 (en) 2016-02-29
WO2014184352A1 (en) 2014-11-20
EP3511018B1 (en) 2021-07-28
HUE044392T2 (hu) 2019-10-28
CN105339003A (zh) 2016-02-17
CN110063935B (zh) 2021-11-09
JP2019034967A (ja) 2019-03-07
PH12015502591B1 (en) 2016-02-29
JP2016520075A (ja) 2016-07-11
ES2731922T3 (es) 2019-11-19
HRP20190954T1 (hr) 2019-07-26
BR112015028411B1 (pt) 2023-01-10
PT2996720T (pt) 2019-07-04
RU2018137504A (ru) 2018-12-14
NL1040254C2 (en) 2014-11-24
EP2996720B1 (en) 2019-03-27
AU2021200035A1 (en) 2021-02-25
CN110063935A (zh) 2019-07-30
US20190010249A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
PH12015502591A1 (en) Stable formulations of immunoglobulin single variable domains and uses thereof
MX2016000739A (es) Composiciones farmacéuticas en polvo seco estables al calor y métodos.
CY1117735T1 (el) Σκευασμα αντισωματος
MX2019000861A (es) Vesicula extracelular que comprende una proteina de fusion que tiene capacidad de union a fc.
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
WO2016200543A8 (en) Aav-mediated expression of anti-influenza antibodies and methods of use thereof
WO2015061416A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
EA201890729A1 (ru) Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками
WO2015051030A8 (en) Stabilized polypeptides and uses thereof
EA201691111A1 (ru) Химерные белки фактора viii и их применение
WO2015038811A3 (en) Liquid protein formulations containing ionic liquids
WO2018050902A3 (en) Multimers, tetramers & octamers
PH12017501473A1 (en) Novel proteins specific for pyoverdine and pyochelin
WO2015058173A8 (en) Stable solid units and methods of making the same
WO2015177175A3 (en) Novel specific-binding polypeptides and uses thereof
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
WO2019136300A3 (en) Anti-mct1 antibodies and uses thereof
EA201691691A1 (ru) Белки слияния tatk-cdkl5, их композиции, составы и применение
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
EA201591609A1 (ru) Варианты альфа-амилазы
BR112018013246A2 (pt) rótulo de peptídeo e proteína rotulada incluindo o mesmo
WO2014150748A3 (en) Stabilized single human cd4 domains and fusion proteins
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
BR112016013577A2 (pt) Proteínas de fusão, seu uso e composição farmacêutica